의료 문서 작성용 AI 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

AI In Medical Writing Market Size, Share, & Trends Analysis Report By Type (Clinical Writing, Type Writing), By End-use (Medical Devices, Pharmaceutical), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,596,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,041,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,930,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

의료 문서 작성용 AI 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 의료 문서 작성용 AI 시장 규모는 2025-2030년에 걸쳐 12.52%의 연평균 성장률(CAGR)을 기록할 전망이며 2030년까지 17억 6,002만 달러에 달할 것으로 예측되고 있습니다.

시장 확대를 이끄는 주요 요인은 의료 산업에서 인공 지능(AI)과 같은 머신 러닝의 수용이 증가하고 있다는 점입니다. 또한 의료비 지출 감소에 대한 수요 증가와 제약 회사의 비용 절감을 위한 R&D 투자 증가도 시장 성장을 촉진하는 또 다른 요인입니다. COVID-19 대유행은 시장에 적당한 영향을 미쳤습니다. 팬데믹으로 인해 연구 개발 활동과 임상 시험이 중단되었습니다.

또한 예산의 한계로 인해 많은 제약 회사들이 투자를 줄였습니다. 팬데믹 초기에는 의료 학술지 투고 건수도 감소하여 시장 성장에 부정적인 영향을 미쳤습니다. 그러나 코로나19 팬데믹 기간 동안 혁신적인 치료법 개발에 있어 기업, 연구 그룹, 정부 기관 간의 협력 노력이 얼마나 중요한지 입증되었습니다. 이에 따라 의료 기기, 생명 공학 및 생명 과학 기업들은 의료 작가에 대한 투자를 늘릴 의향이 있습니다. 따라서 코로나19 팬데믹 기간 동안 의료 업계에서 AI에 대한 수요가 증가하고 있습니다.

의료 문서 작성용 AI 시장 보고서 하이라이트

• 유형별로 타이핑 부문은 당국에 규제 문서를 제출해야하기 때문에 2024년 전체 수익의 32.89%를 차지하여 시장을 지배했습니다. 따라서 이 부문의 의료 문서 작성에서 AI에 대한 수요가 증가했습니다.
• 최종 용도를 기준으로 제약 부문은 2024년 33.33%의 매출 점유율로 시장을 지배했습니다.
• 높은 점유율은 신약 및 치료법 개발을 위한 R&D 활동에 대한 막대한 투자로 인해 이 최종 용도 부문에서 의료 문서 작성에 대한 AI 수요가 증가했기 때문입니다.
• 2024년 북미는 지속적인 기술 발전, 의료 인프라 증가, 많은 수의 약물 임상 시험 및 승인으로 인해 30.12%의 매출 점유율로 시장을 지배했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 의료 문서 작성용 AI 시장의 변수, 동향, 범위

• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
  • 시장 기회
• 의료 문서 작성 분석 툴에 있어서의 AI
  • 산업 분석 - Porter's Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석
  • 사례 연구

제4장 의료 문서 작성용 AI : 유형별, 추정 및 동향 분석

• 유형별 시장 점유율(2024년, 2030년)
• 부문 대시보드
• 제품 유형별 의료 문서 작성에 있어서의 세계의 AI 시장 전망
• 임상 조명
• 과학 논문 작문
• 유형별 라이팅
• 기타

제5장 의료 문서 작성용 AI: 최종 용도별, 추정 및 동향 분석

• 최종 용도 시장 점유율(2024년, 2030년)
• 부문 대시보드
• 최종 용도별 의료 문서 작성에 있어서의 세계의 AI 시장 전망
• 의료기기
• 제약
• 생명공학
• 기타

제6장 의료 문서 작성용 AI : 지역 추정 및 동향 분석, 제품별, 유형별, 최종 용도별

• 지역별 시장 점유율 분석(2024년, 2030년)
• 지역별 시장 대시보드
• 세계의 지역 시장 현황
• 시장 규모와 예측 동향 분석(2018-2030년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제7장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
• 기업, 경쟁의 분류
• 주요 기업의 시장 점유율 및 포지셔닝 분석(2024년)
• 기업 프로파일
  • Parexel International(MA) Corporation
  • Trilogy Writing &Consulting GmbH
  • Freyr
  • Cactus Communications
  • GENINVO
  • IQVIA Inc.
  • ICON plc
  • Syneos Health
  • IBM
  • Teladoc Health, Inc.
  • SmarterDx
  • Abridge Al, Inc.
  • Suki AI, Inc.
  • Movano
  • Heidi
  • Corti
  • Tortus AI.
  • Nabla Technologies

HBR

영문 목차

영문목차

AI In Medical Writing Market Growth & Trends:

The global AI in medical writing market size is anticipated to reach USD 1,760.02 million by 2030, registering a CAGR of 12.52% from 2025 to 2030, according to a new report by Grand View Research, Inc. The primary factor driving the market expansion is the growing acceptance of machine learning, such as Artificial Intelligence(AI), in the healthcare industry. Moreover, the rising demand for reducing healthcare expenditures and increasing R&D investments by pharmaceutical companies to reduce expenses are other factors that are propelling market growth. The COVID-19 pandemic had affected the market moderately. The pandemic caused a pause in research and development activities as well as clinical trials.

Moreover, budgetary limitations led many pharmaceutical companies to reduce their investments. The initial stages of the pandemic also resulted in a decrease in submissions to healthcare journals, negatively impacting market growth. However, the significance of collaborative efforts between companies, research groups, and government bodies in the development of innovative therapies was demonstrated during the COVID-19 pandemic. Consequently, medical device, biotechnology, and life science companies have intentions to boost their investment in medical writers. Thus, increasing the demand for AI in the healthcare industry during the COVID-19 pandemic.

AI In Medical Writing Market Report Highlights:

• Based on type, the typewriting segment dominated the market with a share of 32.89% of the overall revenue in 2024 due to the necessity of submitting regulatory documents to the authorities. Thus, boosting the demand for AI in medical writing in this segment
• Based on end-use, the pharmaceutical segment dominated the market with a revenue share of 33.33% in 2024.
• The high share was attributed to the heavy investments in R&D activities to develop new drugs and treatments, which augmented the demand for AI in medical writing in this end-use segment
• In 2024, North America dominated the market with a revenue share of 30.12% owing to the continuous technological advancements, increasing healthcare infrastructure, and a high number of drug trials & their approvals

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Type
  • 1.1.2. End Use
  • 1.1.3. Regional scope
  • 1.1.4. Estimates and forecast timeline.
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. End use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. AI in Medical Writing Market Variables, Trends & Scope

• 3.1. Market Dynamics
  • 3.1.1. Market driver analysis
  • 3.1.2. Market restraint analysis
  • 3.1.3. Market Opportunities
• 3.2. AI in Medical Writing Market Analysis Tools
  • 3.2.1. Industry Analysis - Porter's
    • 3.2.1.1. Supplier power
    • 3.2.1.2. Buyer power
    • 3.2.1.3. Substitution threat
    • 3.2.1.4. Threat of new entrant
    • 3.2.1.5. Competitive rivalry
  • 3.2.2. PESTEL Analysis
    • 3.2.2.1. Political landscape
    • 3.2.2.2. Economic landscape
    • 3.2.2.3. Social landscape
    • 3.2.2.4. Technological landscape
    • 3.2.2.5. Environmental landscape
    • 3.2.2.6. Legal landscape
  • 3.2.3. COVID-19 Impact Analysis
  • 3.2.4. Case Studies

Chapter 4. AI in Medical Writing Market: Type Estimates & Trend Analysis

• 4.1. Type Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global AI in Medical Writing Market by Product Type Outlook
• 4.4. Clinical Writing
  • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.5. Scientific Writing
  • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.6. Type Writing
  • 4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. AI in Medical Writing Market: End Use Estimates & Trend Analysis

• 5.1. End Use Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global AI in Medical Writing Market by End Use Outlook
• 5.4. Medical Devices
  • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.5. Pharmaceutical
  • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.6. Biotechnology
  • 5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. AI in Medical Writing Market: Regional Estimates & Trend Analysis, By Product, By Type, By End Use

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 6.5. North America
  • 6.5.1. U.S.
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Canada
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Mexico
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Europe
  • 6.6.1. UK
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Germany
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. France
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.4. Italy
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/ reimbursement structure
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.5. Spain
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/ reimbursement structure
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Norway
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/ reimbursement structure
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.7. Sweden
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory framework/ reimbursement structure
    • 6.6.7.3. Competitive scenario
    • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.8. Denmark
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory framework/ reimbursement structure
    • 6.6.8.3. Competitive scenario
    • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. China
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. India
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Australia
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.5. South Korea
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/ reimbursement structure
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.6. Thailand
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory framework/ reimbursement structure
    • 6.7.6.3. Competitive scenario
    • 6.7.6.4. Singapore market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/ reimbursement structure
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.2. Argentina
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/ reimbursement structure
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Regulatory framework/ reimbursement structure
    • 6.9.1.3. Competitive scenario
    • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework/ reimbursement structure
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.3. UAE
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework/ reimbursement structure
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.4. Kuwait
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework/ reimbursement structure
    • 6.9.4.3. Competitive scenario
    • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Key company market share/position analysis, 2024
• 7.4. Company Profiles
  • 7.4.1. Parexel International (MA) Corporation.
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Technology Type benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Trilogy Writing & Consulting GmbH
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Technology Type benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. Freyr
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Technology Type benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Cactus Communications
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Technology Type benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. GENINVO
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Technology Type benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. IQVIA Inc.
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Technology Type benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. ICON plc
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Technology Type benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. Syneos Health
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Technology Type benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. IBM
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Technology Type benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. Teladoc Health, Inc.
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Technology Type benchmarking
    • 7.4.10.4. Strategic initiatives
  • 7.4.11. SmarterDx
    • 7.4.11.1. Company overview
    • 7.4.11.2. Financial performance
    • 7.4.11.3. Technology Type benchmarking
    • 7.4.11.4. Strategic initiatives
  • 7.4.12. Abridge Al, Inc.
    • 7.4.12.1. Company overview
    • 7.4.12.2. Financial performance
    • 7.4.12.3. Technology Type benchmarking
    • 7.4.12.4. Strategic initiatives
  • 7.4.13. Suki AI, Inc.
    • 7.4.13.1. Company overview
    • 7.4.13.2. Financial performance
    • 7.4.13.3. Technology Type benchmarking
    • 7.4.13.4. Strategic initiatives
  • 7.4.14. Movano
    • 7.4.14.1. Company overview
    • 7.4.14.2. Financial performance
    • 7.4.14.3. Technology Type benchmarking
    • 7.4.14.4. Strategic initiatives
  • 7.4.15. Heidi
    • 7.4.15.1. Company overview
    • 7.4.15.2. Financial performance
    • 7.4.15.3. Technology Type benchmarking
    • 7.4.15.4. Strategic initiatives
  • 7.4.16. Corti
    • 7.4.16.1. Company overview
    • 7.4.16.2. Financial performance
    • 7.4.16.3. Technology Type benchmarking
    • 7.4.16.4. Strategic initiatives
  • 7.4.17. Tortus AI.
    • 7.4.17.1. Company overview
    • 7.4.17.2. Financial performance
    • 7.4.17.3. Technology Type benchmarking
    • 7.4.17.4. Strategic initiatives
  • 7.4.18. Nabla Technologies
    • 7.4.18.1. Company overview
    • 7.4.18.2. Financial performance
    • 7.4.18.3. Technology Type benchmarking
    • 7.4.18.4. Strategic initiatives

관련자료